Mouse-human immunoglobulin G1 chimeric antibodies with activities against Cryptococcus neoformans

S. L. Zebedee, R. K. Koduri, J. Mukherjee, S. Mukherjee, S. Lee, D. F. Sauer, Matthew D. Scharff, A. Casadevall

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

Passive antibody administration is a potentially useful approach for the therapy of human Cryptococcus neoformans infections. To evaluate the efficacy of the human immunoglobulin G1 (IgG1) constant region against C. neoformans and to construct murine antibody derivatives with reduced immunogenicities and longer half-lives in humans, two mouse-human IgG1 chimeric antibodies were generated from the protective murine monoclonal antibodies 2D10 (IgM) and 18B7 (IgG1). The 2D10 mouse-human IgG1 chimeric antibody (ch2D10) had significantly lower binding affinity than its parent murine antibody (m2D10), presumably because of a loss of avidity contribution on switching from IgM to IgG. The 18B7 mouse-human IgG1 chimeric antibody (ch18B7) had higher affinity for cryptococcal polysaccharide antigen than its parent murine antibody (m18B7). ch18B7 and ch2D10 promoted phagocytosis of C. neoformans by primary human microglial cells and the murine J774.16 macrophage-like cell line. ch18B7 and m18B7 enhanced fungistatic or fungicidal activity of J774.16 cells and prolonged the survival of lethally infected mice. We conclude that the human IgG1 constant chain can be effective in mediating antifungal activity against C. neoformans. ch18B7 or similar antibodies are potential candidates for passive antibody therapy of human cryptococcosis.

Original languageEnglish (US)
Pages (from-to)1507-1514
Number of pages8
JournalAntimicrobial Agents and Chemotherapy
Volume38
Issue number7
StatePublished - 1994

Fingerprint

Cryptococcus neoformans
Immunoglobulins
Antibodies
Immunoglobulin M
Immunoglobulin Constant Regions
Cryptococcosis
Phagocytosis
Cell Survival
Immunoglobulin G
Macrophages
Monoclonal Antibodies
Antigens
Cell Line

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Zebedee, S. L., Koduri, R. K., Mukherjee, J., Mukherjee, S., Lee, S., Sauer, D. F., ... Casadevall, A. (1994). Mouse-human immunoglobulin G1 chimeric antibodies with activities against Cryptococcus neoformans. Antimicrobial Agents and Chemotherapy, 38(7), 1507-1514.

Mouse-human immunoglobulin G1 chimeric antibodies with activities against Cryptococcus neoformans. / Zebedee, S. L.; Koduri, R. K.; Mukherjee, J.; Mukherjee, S.; Lee, S.; Sauer, D. F.; Scharff, Matthew D.; Casadevall, A.

In: Antimicrobial Agents and Chemotherapy, Vol. 38, No. 7, 1994, p. 1507-1514.

Research output: Contribution to journalArticle

Zebedee, SL, Koduri, RK, Mukherjee, J, Mukherjee, S, Lee, S, Sauer, DF, Scharff, MD & Casadevall, A 1994, 'Mouse-human immunoglobulin G1 chimeric antibodies with activities against Cryptococcus neoformans', Antimicrobial Agents and Chemotherapy, vol. 38, no. 7, pp. 1507-1514.
Zebedee SL, Koduri RK, Mukherjee J, Mukherjee S, Lee S, Sauer DF et al. Mouse-human immunoglobulin G1 chimeric antibodies with activities against Cryptococcus neoformans. Antimicrobial Agents and Chemotherapy. 1994;38(7):1507-1514.
Zebedee, S. L. ; Koduri, R. K. ; Mukherjee, J. ; Mukherjee, S. ; Lee, S. ; Sauer, D. F. ; Scharff, Matthew D. ; Casadevall, A. / Mouse-human immunoglobulin G1 chimeric antibodies with activities against Cryptococcus neoformans. In: Antimicrobial Agents and Chemotherapy. 1994 ; Vol. 38, No. 7. pp. 1507-1514.
@article{745c2bec26f24e0395c95ff13853c739,
title = "Mouse-human immunoglobulin G1 chimeric antibodies with activities against Cryptococcus neoformans",
abstract = "Passive antibody administration is a potentially useful approach for the therapy of human Cryptococcus neoformans infections. To evaluate the efficacy of the human immunoglobulin G1 (IgG1) constant region against C. neoformans and to construct murine antibody derivatives with reduced immunogenicities and longer half-lives in humans, two mouse-human IgG1 chimeric antibodies were generated from the protective murine monoclonal antibodies 2D10 (IgM) and 18B7 (IgG1). The 2D10 mouse-human IgG1 chimeric antibody (ch2D10) had significantly lower binding affinity than its parent murine antibody (m2D10), presumably because of a loss of avidity contribution on switching from IgM to IgG. The 18B7 mouse-human IgG1 chimeric antibody (ch18B7) had higher affinity for cryptococcal polysaccharide antigen than its parent murine antibody (m18B7). ch18B7 and ch2D10 promoted phagocytosis of C. neoformans by primary human microglial cells and the murine J774.16 macrophage-like cell line. ch18B7 and m18B7 enhanced fungistatic or fungicidal activity of J774.16 cells and prolonged the survival of lethally infected mice. We conclude that the human IgG1 constant chain can be effective in mediating antifungal activity against C. neoformans. ch18B7 or similar antibodies are potential candidates for passive antibody therapy of human cryptococcosis.",
author = "Zebedee, {S. L.} and Koduri, {R. K.} and J. Mukherjee and S. Mukherjee and S. Lee and Sauer, {D. F.} and Scharff, {Matthew D.} and A. Casadevall",
year = "1994",
language = "English (US)",
volume = "38",
pages = "1507--1514",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "7",

}

TY - JOUR

T1 - Mouse-human immunoglobulin G1 chimeric antibodies with activities against Cryptococcus neoformans

AU - Zebedee, S. L.

AU - Koduri, R. K.

AU - Mukherjee, J.

AU - Mukherjee, S.

AU - Lee, S.

AU - Sauer, D. F.

AU - Scharff, Matthew D.

AU - Casadevall, A.

PY - 1994

Y1 - 1994

N2 - Passive antibody administration is a potentially useful approach for the therapy of human Cryptococcus neoformans infections. To evaluate the efficacy of the human immunoglobulin G1 (IgG1) constant region against C. neoformans and to construct murine antibody derivatives with reduced immunogenicities and longer half-lives in humans, two mouse-human IgG1 chimeric antibodies were generated from the protective murine monoclonal antibodies 2D10 (IgM) and 18B7 (IgG1). The 2D10 mouse-human IgG1 chimeric antibody (ch2D10) had significantly lower binding affinity than its parent murine antibody (m2D10), presumably because of a loss of avidity contribution on switching from IgM to IgG. The 18B7 mouse-human IgG1 chimeric antibody (ch18B7) had higher affinity for cryptococcal polysaccharide antigen than its parent murine antibody (m18B7). ch18B7 and ch2D10 promoted phagocytosis of C. neoformans by primary human microglial cells and the murine J774.16 macrophage-like cell line. ch18B7 and m18B7 enhanced fungistatic or fungicidal activity of J774.16 cells and prolonged the survival of lethally infected mice. We conclude that the human IgG1 constant chain can be effective in mediating antifungal activity against C. neoformans. ch18B7 or similar antibodies are potential candidates for passive antibody therapy of human cryptococcosis.

AB - Passive antibody administration is a potentially useful approach for the therapy of human Cryptococcus neoformans infections. To evaluate the efficacy of the human immunoglobulin G1 (IgG1) constant region against C. neoformans and to construct murine antibody derivatives with reduced immunogenicities and longer half-lives in humans, two mouse-human IgG1 chimeric antibodies were generated from the protective murine monoclonal antibodies 2D10 (IgM) and 18B7 (IgG1). The 2D10 mouse-human IgG1 chimeric antibody (ch2D10) had significantly lower binding affinity than its parent murine antibody (m2D10), presumably because of a loss of avidity contribution on switching from IgM to IgG. The 18B7 mouse-human IgG1 chimeric antibody (ch18B7) had higher affinity for cryptococcal polysaccharide antigen than its parent murine antibody (m18B7). ch18B7 and ch2D10 promoted phagocytosis of C. neoformans by primary human microglial cells and the murine J774.16 macrophage-like cell line. ch18B7 and m18B7 enhanced fungistatic or fungicidal activity of J774.16 cells and prolonged the survival of lethally infected mice. We conclude that the human IgG1 constant chain can be effective in mediating antifungal activity against C. neoformans. ch18B7 or similar antibodies are potential candidates for passive antibody therapy of human cryptococcosis.

UR - http://www.scopus.com/inward/record.url?scp=0028334517&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028334517&partnerID=8YFLogxK

M3 - Article

C2 - 7979280

AN - SCOPUS:0028334517

VL - 38

SP - 1507

EP - 1514

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 7

ER -